We used the prostate cancer line C4-2b for this analysis because the basal level of PARP7 expression is extremely low in these cells, RBN2397 treatment alone has no effect on growth of these cells, and activation of AHR signaling sensitizes the cells to RBN2397 inhibition (Supplementary Fig. S4C). Here, TIPARP is linked to prostate cancer.